Early results from clinical trials on substances like MDMA and psilocybin have been encouraging. In the middle of what is often regarded as a mental health crisis, many of these initiatives target a few of the most expensive and challenging mental health conditions while they are still happening. Researchers and executives discussed how that might convince health insurers, or “payors,” to jump on board during a Perspective on Psychedelics conference in New York.
The league pulled marijuana off its banned list in the new players’ agreement. In the…
In New South Wales, Australia, patients can legally use medical cannabis with a prescription. So…
The clinical evidence is real. The valuations are not. Compass Pathways: $560 million market cap,…
Reading through hundreds of grower responses, one theme emerges above the specific challenges: growing cannabis…
The Tri-State brand built its reputation one pre-roll at a time. Now, after multiple Cannabis…
The Mobb Deep co-founder and Queensbridge native opens The Bridge in Astoria this weekend, with…